Locilex

Locilex™

Cytolex™, MSI-78, pexiganan acetate Infectious disease A topical antibiotic for treating infected diabetic foot ulcers; Locilex is the first in a class of antibiotic/anti-infective magainins, derived from the skin secretions of the African clawed frog, which kill bacteria by attacking cell membranes. See Magainin. Note: It was deemed not approvable.
References in periodicals archive ?
NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialisation of Locilex (pexiganan cream 0.
Dipexium Closes Merger with Asprin Delivery Specialist PLx Pharma in Stock Deal
a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
United States : Dipexium Pharmaceuticals reports third quarter 2016 financial results
M2 PHARMA-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
The first two topical antibacterials, Innocoll's Cogenzia (gentamicin-collagen sponge) and Dipexium Pharmaceuticals' Locilex (pexiganan acetate cream 1%), are also expected to launch in the US and the five major EU markets (5EU).
"OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017" Published
She has been assigned to work on the SmithKline Beecham Locilex account.
Thomas Ferguson Associates Strengthens Account and Creative Teams to Heighten Client Service
today announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.
United States : Dipexium announces top-line data from OneStep Phase 3 trials with Locilex in mild diabetic foot infection did not meet primary clinical endpoint of superiority versus vehicle plus standardized wound care
M2 PHARMA-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium recently completed its pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the United States under a Special Protocol Assessment (SPA) agreement from the US Food and Drug Administration (FDA).
Dipexium passes EMA's SME designation
Dipexium" or the "Company"), a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
United States : Dipexium receives European medicines agency designation as a small and medium enterprise
M2 EQUITYBITES-February 5, 2016-Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
M2 EQUITYBITES-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
M2 EQUITYBITES-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Medical browser ?
Full browser ?